ReviewFrontiers in immunology2023
Telitacicept for autoimmune nephropathy.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06125405 (Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Dual BAFF/APRIL inhibition with telitacicept in systemic lupus erythematosus and IgA nephropathy: pharmacological rationale, clinical efficacy, and safety on female fertility preservation.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy.International urology and nephrology · 2026Article
- The liver-secreted protein FGL1 restrains a subset of innate-like B cell responses via the receptor TACI.Immunity · 2026Article
- Telitacicept for pediatric Henoch-Schönlein purpura nephritis: analytical populations and safety monitoring.Clinical rheumatology · 2026Article
- Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.Kidney medicine · 2026Review
- Timing of treatment-switch to telitacicept in high-risk IgA nephropathy: an observational case series of two clinical scenarios.BMC nephrology · 2026Observational
- Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study.Lupus science & medicine · 2026Article
- Telitacicept for childhood HSPN: A prospective self-controlled study.Clinical rheumatology · 2026Article
- Review
- A BAFF/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study.Arthritis research & therapy · 2026Observational
- The efficacy and safety of telitacicept and its combination with glucocorticoids in IgA nephropathy: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Autoantibody repertoire in lupus nephritis: from pathogenic mechanisms to clinical integration for precision decision-making.Frontiers in immunology · 2026Review
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
- BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis.Frontiers in immunology · 2026Review
- Efficacy and safety of telitacicept in systemic lupus erythematosus: a single-center, retrospective, real-world study.Frontiers in immunology · 2026Article
- Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.Frontiers in pediatrics · 2026Article
- Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.Frontiers in immunology · 2026Article
- Efficacy and safety of telitacicept in the treatment of immunoglobulin a nephropathy: a real-world, single-center, retrospective study.BMC nephrology · 2025Article
- Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.Renal failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cells and the humoral immunity are important players in the pathogenesis of autoimmune diseases. BAFF (also known as BLYS) and a proliferation-inducing ligand APRIL are required for the maintenance of the B-cell pool and humoral immunity. BAFF and APRIL can promote B-cell differentiation, maturation, and plasma cell antibody secretion. BAFF/APRIL overexpression has been identified in several autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, IgA nephropathy, etc. Telitacicept, a novel fully human TACI-Fc fusion protein that binds both BAFF and APRIL, was approved in China in March 2021 for the treatment of systemic lupus erythematosus at a recommended dose of 160 mg/w subcutaneously and is in clinical trials for the treatment of multiple indications in other autoimmune diseases. In this review, we explored telitacicept's mechanism of action and clinical data. In addition, the immune features of autoimmune nephropathy were discussed, emphasizing lupus nephritis, IgA nephropathy, and membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.